Emile Nuwaysir, PhD, brings broad life science leadership experience to the Invenra Board. Most recently, he served as President and CEO of BlueRock Therapeutics, a company founded by Versant Ventures and Bayer AG, leading the company through its 2019 acquisition by Bayer. Prior to BlueRock, he was the President of a regenerative medicine division of Fujifilm (Cellular Dynamics International, Inc. – a Fujifilm Company) and President of Opsis Therapeutics, a biotech developing cell therapies for the retina. Prior to that, Emile was Chief Operating Officer of Cellular Dynamics International (CDI) where he helped manage growth from pre-revenue startup to a public company traded on NASDAQ, through the S1 SEC filing, IPO roadshow, public company management and the ultimate acquisition by FujiFilm for $307M. Prior to CDI, he was the SVP of Program Management and Chief Technical Officer at Roche NimbleGen, a division of Roche Diagnostics, where he oversaw product portfolio and lifecycle management, managed all Business Development activities and all R&D activities. Prior to Roche, he was VP of Business Development at NimbleGen Systems, where, as the second employee, he helped build the company and its products, raise capital, prepare for an IPO, and successfully orchestrate a "dual-track" IPO process leading to the take-out sale by Roche for $273M. He received his Ph.D. from the University of Wisconsin-Madison and completed postdoctoral fellowships at the National Institutes of Health and UNC-Chapel Hill.